GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTAW) » Definitions » EV-to-FCF

Pasithea Therapeutics (Pasithea Therapeutics) EV-to-FCF : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pasithea Therapeutics's Enterprise Value is $0.00 Mil. Pasithea Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-13.73 Mil. Therefore, Pasithea Therapeutics's EV-to-FCF for today is 0.00.

The historical rank and industry rank for Pasithea Therapeutics's EV-to-FCF or its related term are showing as below:

KTTAW' s EV-to-FCF Range Over the Past 10 Years
Min: 0.45   Med: 3.01   Max: 9.3
Current: 0.45

During the past 4 years, the highest EV-to-FCF of Pasithea Therapeutics was 9.30. The lowest was 0.45. And the median was 3.01.

KTTAW's EV-to-FCF is ranked better than
78.27% of 382 companies
in the Biotechnology industry
Industry Median: 8.405 vs KTTAW: 0.45

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-08), Pasithea Therapeutics's stock price is $0.0134. Pasithea Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.000. Therefore, Pasithea Therapeutics's PE Ratio for today is N/A.


Pasithea Therapeutics EV-to-FCF Historical Data

The historical data trend for Pasithea Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics EV-to-FCF Chart

Pasithea Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- 3.83 1.32 0.66

Pasithea Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 0.92 0.72 0.66 0.32

Competitive Comparison of Pasithea Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Pasithea Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pasithea Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's EV-to-FCF falls into.



Pasithea Therapeutics EV-to-FCF Calculation

Pasithea Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.000/-13.729
=0.00

Pasithea Therapeutics's current Enterprise Value is $0.00 Mil.
Pasithea Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pasithea Therapeutics  (NAS:KTTAW) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pasithea Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0134/0.000
=N/A

Pasithea Therapeutics's share price for today is $0.0134.
Pasithea Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pasithea Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pasithea Therapeutics (Pasithea Therapeutics) Business Description

Traded in Other Exchanges
Address
1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.